US Insurer Aetna to Reimburse Gilead Hepatitis Drug

The largest US health insurer, Aetna, has negotiated a discount for Gilead Sciences' hepatitis C treatment regime and said it plans to offer this as a preferred choice for its nearly 11 million commercial customers.

Aetna and other US insurers have resisted the high price of hepatitis C treatments.

Days after the Federal Drug Administration (FDA) approved AbbVie's Viekira Pak on Dec. 19 last year, the country's largest pharmacy benefit manager, Express Scripts, said it had negotiated a cheaper price.

In most cases, Express said it would no longer reimburse Gilead's Sovaldi - which costs $84,000 for the 12-week course of therapy - for patients who have the genotype 1 form of the disease (70% of US patients). This, it said, was unaffordable.

Gilead's latest Hepatitis treatment, Harvoni, combines Sovaldi with another drug. The one-pill, once-a-day treatment, which lists at $94,500 for 12 weeks, is claimed to boast cure rates well above 90%.

CVS Health Corp, one of the largest US managers of drug benefits, said it would give preferred status to the Gilead hepatitis C treatments and cover the AbbVie drug only as an exception.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.